Imatinib Zentiva

Imatinib mesilate, the active ingredient in Imatinib Zentiva, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib Zentiva acts on abnormal tyrosine‑kinase signaling pathways that drive certain hematologic and solid tumours.

- Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves long‑term survival. - Gastrointestinal stromal tumor (GIST): blocks KIT‑driven tumor growth and prolongs progression‑free survival. - Philadelphia‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission when used with chemotherapy.

Imatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Edema: swelling of the hands, feet, or face. - Fatigue: persistent tiredness. - Diarrhea: loose stools. - Rash: skin irritation or redness. - Muscle cramps: involuntary tightening of muscles.

Serious or Rare Side Effects: - Neutropenia: dangerously low white‑blood‑cell count. - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: reduced heart pumping ability. - Severe hemorrhage: abnormal bleeding. - Interstitial lung disease: inflammation of lung tissue. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Before initiating therapy, clinicians should assess baseline health status and monitor patients regularly. - Blood count monitoring: check complete blood count frequently to detect cytopenias. - Liver function assessment: evaluate hepatic enzymes before and during treatment. - Cardiac evaluation: perform ECG or echocardiogram in patients with pre‑existing heart disease. - Hypersensitivity warning: discontinue if severe allergic reaction occurs. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase imatinib exposure and toxicity. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce plasma levels and efficacy. - Warfarin: concurrent use can enhance anticoagulant effect and raise bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., midazolam, tacrolimus): may require dose adjustment of the co‑administered drug. - Diuretics (e.g., furosemide): can increase plasma concentration of imatinib, warranting close monitoring.